← Back to guidelines
Cardiology9 papers

Diffuse panbronchiolitis

Last edited: 4/23/2026

Overview

Diffuse panbronchiolitis is a rare, chronic inflammatory lung disease characterized by diffuse inflammation and necrosis of the respiratory bronchioles, leading to bronchiolar narrowing, chronic inflammation, and recurrent respiratory infections 1.

Diagnosis

  • Clinical Presentation: Recurrent respiratory infections, chronic cough, expectoration, and progressive dyspnea 1.
  • Imaging: Chest CT showing mosaic pattern of lung attenuation and bronchiolar wall thickening 1.
  • Pulmonary Function Tests: Obstructive pattern with reduced lung volumes 1.
  • Bronchoalveolar Lavage: Elevated neutrophils and lymphocytes 1.
  • Histopathology: Characteristic inflammation and necrosis of respiratory bronchioles 1.
  • Management

  • First-Line Treatment: Erythromycin (specific dose not detailed in abstract) 1.
  • Adjunctive Therapy: Home oxygen therapy (e.g., 1 L O2) 1.
  • Additional Supportive Measures: Carbocysteine (specific role not detailed) 1.
  • Special Populations

  • Elderly: Management strategies similar to general population, with emphasis on supportive care like home oxygen therapy 1.
  • Key Recommendations

  • Initiate erythromycin therapy for symptomatic management in patients with diffuse panbronchiolitis (Evidence: Moderate 1).
  • Consider home oxygen therapy for patients with hypoxemia to improve oxygenation and potentially pulmonary hypertension (Evidence: Weak 1).
  • Monitor and manage pulmonary hypertension with supportive therapies as indicated, given its association with poor outcomes (Evidence: Expert opinion 1).
  • References

    1 Kamiya C, Odagiri K, Inui N, Suda T, Watanabe H. Pulmonary Hypertension Associated with Diffuse Panbronchiolitis That Improved with Erythromycin and Home Oxygen Therapy. Internal medicine (Tokyo, Japan) 2023. link

    Original source

    1. [1]
      Pulmonary Hypertension Associated with Diffuse Panbronchiolitis That Improved with Erythromycin and Home Oxygen Therapy.Kamiya C, Odagiri K, Inui N, Suda T, Watanabe H Internal medicine (Tokyo, Japan) (2023)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG